LINKER-MM1: Linvoseltamab Shows Promise Across High-Risk Myeloma | EHA 2026

High-risk multiple myeloma remains one of the greatest challenges in patient care, with certain genetic abnormalities and disease features leading to earlier relapse and poorer outcomes. At EHA 2026, researchers presented a subgroup analysis from the LINKER-MM1 study evaluating the BCMA-targeted bispecific antibody Linvoseltamab in patients with high-risk relapsed/refractory multiple myeloma.

In this video, we review how patients with high-risk cytogenetics, extramedullary disease, and other adverse prognostic factors responded to treatment. Learn about overall response rates, depth of response, durability of remission, safety findings, and what these results could mean for future treatment options in difficult-to-treat multiple myeloma.

Subscribe for the latest updates from EHA 2026, ASH, ASCO, IMS, and other leading myeloma conferences, featuring expert interviews and easy-to-understand explanations of the newest research.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.